Aclaris Therapeutics Inc (ACRS)

[ADVFN_bioking]

ACRS..Eskata approval likely next week guys , 10 months review timeline like in USA so approval should come next week


Price $1.17 ...Market cap $48 Million ...Cash $115Million ...Book Value $3.30 ...Cash per Share $2.79

Cipher Pharmaceuticals Announces A-101 40% Topical Solution Accepted for Review by Health Canada
https://cipher.investorroom.com/2018-12-18-Cipher-Pharmaceuticals-Announces-A-101-40-Topical-Solution-Accepted-for-Review-by-Health-Canada

Dec. 18, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) today announced that its New Drug Submission ("NDS") for A-101 40% topical solution ("A-101 40%") for the treatment of raised seborrheic keratoses ("SKs") has been accepted for review by Health Canada. Cipher acquired the exclusive Canadian rights to distribute and commercialize A-101 40% from Aclaris Therapeutics, Inc. (NASDAQ:ACRS) ("Aclaris") in April 2018.

A-101 40% is a U.S. Food and Drug Administration ("FDA")-approved product indicated for the treatment of raised SKs, which are commonly occurring non-cancerous skin growths that affect more than 9 million Canadian adults and can be an aesthetic skin concern. A-101 40% was approved by the FDA in December 2017 and is marketed by Aclaris in the U.S. under the tradename Eskata .